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Results Imatinib treatment decreased plasma IgA and 
IgG levels, while dasatinib reduced IgM levels. At diag-
nosis, the proportion of patients with IgA, IgG, and IgM 
levels below the lower limit of normal (LLN) was 0, 11, 
and 6% of all CML patients, respectively, whereas at 12 
months timepoint the proportions were 6% (p = 0.13), 31% 
(p = 0.042) and 28% (p = 0.0078). Lower initial Ig levels 
predisposed to the development of hypogammaglobuline-
mia during TKI therapy. Decreased Ig levels in imatinib-
treated patients were associated with higher percentages of 
immature BM B cells. The patients, who had low Ig lev-
els during the TKI therapy, had significantly more frequent 
minor infections during the follow-up compared with the 
patients with normal Ig values (33% vs. 3%, p = 0.0016). 
No severe infections were reported, except recurrent upper 
Abstract 
Purpose Tyrosine kinase inhibitors (TKIs) have well-
characterized immunomodulatory effects on T and NK 
cells, but the effects on the humoral immunity are less well 
known. In this project, we studied TKI-induced changes in 
B cell-mediated immunity.
Methods We collected peripheral blood (PB) and bone 
marrow (BM) samples from chronic myeloid leuke-
mia (CML) patients before and during first-line imatinib 
(n = 20), dasatinib (n = 16), nilotinib (n = 8), and bosutinib 
(n = 12) treatment. Plasma immunoglobulin levels were 
measured, and different B cell populations in PB and BM 
were analyzed with flow cytometry.
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respiratory tract infections in one imatinib-treated patient, 
who developed severe hypogammaglobulinemia.
Conclusions TKI treatment decreases plasma Ig lev-
els, which should be measured in patients with recurrent 
infections.
Keywords CML · Tyrosine kinase inhibitor · B cell · 
Immunoglobulin
Introduction
Chronic myeloid leukemia (CML) originates from a hemat-
opoietic stem cell carrying the Philadelphia (Ph) chromo-
some and an oncogenic BCR-ABL1 fusion gene, which 
encodes for a constitutively active tyrosine kinase. Cur-
rent therapy for CML is based on tyrosine kinase inhibi-
tors (TKIs) imatinib, nilotinib, dasatinib, or bosutinib. The 
first-generation TKI imatinib has been proved to be both 
safe and efficient, radically improving the outcome of CML 
patients (Druker et  al. 2006; Hochhaus et  al. 2009). The 
second-generation TKIs nilotinib and dasatinib were origi-
nally used as a second-line treatment for patients resistant 
or intolerant to imatinib treatment. However, as they appear 
to be more effective than imatinib and generally well toler-
ated, they are now also being used as a first-line therapy 
for CML (Kantarjian et al. 2010, 2011). Bosutinib is one of 
the newest members in the TKI family, and it is used as a 
second or third line option in CML patients resistant for or 
intolerant to imatinib, dasatinib, or nilotinib (Khoury et al. 
2012).
Although the main target of TKIs is the BCR-ABL1 
kinase, they all have a distinct inhibitory profile and affect 
several other kinases as well (Hantschel et  al. 2008). 
Related to the inhibition of these off-target kinases, all 
TKIs have potential impact on the immune system and 
several in  vitro studies have suggested mostly immuno-
suppressive effects (Ilander et  al. 2014). In B cells, ABL 
kinase phosphorylates B cell co-receptor CD19, and thus 
may regulate the B cell proliferation (Zipfel et  al. 2000). 
Accordingly, ABL knockout mice show severe defects in B 
and T cell development (Tybulewicz et al. 1991). Neutro-
penia and thrombocytopenia are common during the first 
months of the TKI therapy. The exact mechanism of these 
cytopenias is not known, but the swift clearance of the Ph+ 
hematopoiesis after the onset of TKI therapy preceding 
the recovery of normal hematopoiesis may have a role in 
addition to the direct inhibitory effects of the TKIs (Tal-
paz et al. 2006; Druker et al. 2006; Quintás-Cardama et al. 
2009). Although B cells are Ph-negative in most untreated 
CML patients, 25% of the patients have predominantly Ph+ 
B cells, or a mixture of Ph+ and Ph-negative B cells in the 
bone marrow (Nitta et  al. 1985; Takahashi et  al. 1998). 
Imatinib has been reported to have suppressive effect on B 
cells with a reduction of IgM+ memory B cells (Lavallade 
et al. 2013) and, for example, dasatinib inhibits B cell sign-
aling through the Lyn kinase, a member of Src family of 
tyrosine kinases, directly affecting the B cell compartment 
(Bantscheff et al. 2007; Rix et al. 2007).
Since CML patients usually need TKI therapy for sev-
eral years or even decades, the immunological off-target 
effects may be of significance in clinical practice. There-
fore, the aim of this project was to study the effects of 
TKI therapy on B cell-mediated immunity in vivo in CML 




Peripheral blood (PB) and bone marrow (BM) samples 
were collected from newly diagnosed chronic phase CML 
patients (n = 44) treated with imatinib (n = 20), dasatinib 
(n = 16), nilotinib (n = 8), and bosutinib (n = 12, only PB 
samples available). The patients took part in different clini-
cal studies: imatinib- and dasatinib-treated patients par-
ticipated in the NordCML006 study cohort (ClinicalTrials.
gov: NCT00852566), nilotinib patients in the ENEST1st 
or ENESTnd study (NCT00519090 and NCT00471497, 
respectively), and bosutinib-treated patients in the BFORE 
study (NCT02130557). Patient samples and clinical data 
were obtained from the following centers: Helsinki Uni-
versity Central Hospital (Helsinki, Finland), Skåne Uni-
versity Hospital (Lund, Sweden), Uppsala University 
Hospital (Uppsala, Sweden), Linköping University Hos-
pital (Linköping, Sweden), Karolinska University Hospi-
tal (Stockholm, Sweden), Norrlands University Hospital 
(Umeå, Sweden), Aarhus University Hospital (Aarhus, 
Denmark), St Olavs Hospital (Trondheim, Norway), 
Haukeland University Hospital (Bergen, Norway), and 
VU University Medical Center (Amsterdam, Netherlands). 
Control samples were obtained from 19 healthy volunteers, 
including 7 volunteers from whom BM samples were also 
taken. The main characteristics of the patients are summa-
rized in Table 1.
Measurement of plasma immunoglobulin levels
ACD, heparin, or EDTA plasma was separated from PB 
and stored in −70 °C. Plasma immunoglobulin (Ig) lev-
els (IgA, IgM, IgG) were measured after thawing with an 
immunoturbidimetric method in the central laboratory of 
the Helsinki University Central Hospital (HUSLAB). The 
Finnish national reference values for the Ig levels were 
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used in the analysis: IgA 0.52–4.84 g/l, IgM 0.36–2.84 g/l, 
IgG 6.8–15 g/l.
Separation of peripheral blood mononuclear cells
Mononuclear cells were separated from PB using Ficoll-
Paque gradient separation (GE Healthcare, Chicago, Illi-
nois, US) according to the manufacturer’s instructions. 
The isolated PB MNCs were cryopreserved in fetal bovine 
serum containing 10% DMSO.
Analysis of PB and BM B cell subclasses by flow 
cytometry
PB and BM samples from CML patients treated with 
imatinib, dasatinib, nilotinib, and bosutinib (only PB) were 
analyzed at diagnosis and 1, 3, 6, and 12 months after the 
start of therapy. The samples were stained with antibod-
ies against CD45, CD3, and CD19. The proportion of 
CD45+CD19+ B cells was analyzed using flow cytom-
etry after the lysis of red blood cells. In the BM samples, 
additional B cell populations were gated to analyze differ-
ent stages of B cell development: CD19+CD45high mature, 
CD19+CD45intermediate maturing, and CD19+CD45low 
immature B cells (Caldwell and Patterson 1987; Shah et al. 
1988). The flow cytometry analysis was performed with 
FACSAriaI/II and FACSDiva software (Becton Dickinson, 
Franklin Lakes, New Jersey, US).
The mature B cells in PB were analyzed in more 
detail at 12 months timepoint by staining PB mononu-
clear cells (PB MNCs) with CD3, CD19, CD27, CD38, 
IgD, and IgM antibodies. B cells were first gated from 
the lymphocyte population as  CD3negCD19+ cells, and 
following subpopulations were gated: CD19+CD27neg 
mature naïve cells, CD19+CD27+ mature memory cells, 
CD19+CD27+IgMnegIgDneg class-switched memory cells, 
CD19+CD27+IgM+IgD+/low marginal zone-like mem-
ory cells, CD19+CD38+IgM+ transitional B cells, and 
CD19+CD38highIgMneg plasmablasts. Samples were ana-
lyzed with FACSVerse and FACSDiva or FACSuite soft-
wares (Becton Dickinson).
All antibodies were purchased from Becton Dickinson.
Statistical analysis
Comparisons of Ig levels and B cell subpopulations were 
done with Mann–Whitney t test, paired t test, or one- or 
two-way ANOVA. Clinical correlations were analyzed by 
Spearman’s. Comparisons of categorical variants between 
groups were done with Chi-square test. p values below 
0.05 were considered as statistically significant. All analy-
ses were performed using either GraphPad Prism version 
6.0 (GraphPad software Inc., California, US) or SPSS ver-
sion 22 (IBM SPSS Statistics, Armonk, New York, US) 
software.
Table 1  Clinical characteristics of the CML patients
Statistical analysis: The means of Sokal score and age were compared with one-way ANOVA. Comparisons of categorical variants, i.e., age and 
hypogammaglobulinemia, were done with Chi-square test. NA not accessible
a Number of patients who had at least ≥2 times Ig values below the lower normal limit during the follow-up
b Ig levels below the lower limit of normal at diagnosis
c Ig levels below the lower limit of normal at 12  months timepoint
Imatinib (n = 20) Dasatinib (n = 16) Nilotinib (n = 8) Bosutinib (n = 12) p value CML, total (n = 56)
Males/females 10/10 6/10 4/4 8/4 0.51 28/28
Age, median (range) 57 (39–77) 49 (39–71) 50 (47–60) 44 (28–77) 0.10 53 (28–77)
Sokal score, median (range) 0.82 (0.58–13.22) 0.81 (0.61–4.2) 0.8 (0.63–1.7) 0.87 (0.51–1.68) 0.98 0.82 (0.51–13.22)
Total  hypogammaglobulinemiaa 7 (35%) 4 (25%) 5 (63%) 3 (25%) 0.27 19 (34%)
HypoIgA at diagnosis, number of 
patients (%)b
0/20 (0%) 0/16 (0%) 0/7 (0%) 0/10 (0%) NA 0/53 (0%)
HypoIgG at diagnosis, number of 
patients (%)b
2/20 (10%) 2/16 (13%) 1/7 (14%) 1/10 (10%) 0.99 6/53 (11%)
HypoIgM at diagnosis, number of 
patients (%)b
0/20 (0%) 1/16 (6%) 1/7 (14%) 1/10 (10%) 0.47 3/53 (6%)
HypoIgA at 12 months, number of 
patients (%)c
1/13 (8%) 0/6 (0%) 1/7 (14%) 0/6 (0%) 0.66 2/32 (6%)
HypoIgG at 12 months, number of 
patients (%)c
6/13 (46%) 2/6 (33%) 2/7 (29%) 0/6 (0%) 0.25 10/32 (31%)
HypoIgM at 12 months, number of 
patients (%)c
3/13 (23%) 2/6 (33%) 1/7 (14%) 3/6 (50%) 0.51 9/32 (28%)
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Results
Imatinib and dasatinib treatment are related to lower 
Ig levels during follow-up
Plasma Ig levels were analyzed at diagnosis and during 
TKI therapy (1, 3, 6, 12, 18, and 24 months after the start 
of therapy). Plasma samples were available from patients 
treated with imatinib (n = 20), dasatinib (n = 16), nilotinib 
(n = 8), or bosutinib (n = 12) and 19 healthy controls.
Median Ig levels of chronic phase CML patients were 
similar to the healthy controls before the onset of TKI 
treatment (Fig.  1a–c). However, imatinib-treated patients 
showed a significant overall decrease of IgA and IgG lev-
els during therapy (p = 0.019 and p = 0.018, respectively) 
(Fig.  1d–f). Dasatinib-treated patients had only decreased 
IgM levels (p = 0.0099) (Fig. 1g–i), and similar trend was 
also observed in bosutinib group, but no statistically sig-
nificant changes were observed. During nilotinib therapy, 
no marked changes in plasma Ig levels were observed 
(Fig. 1j–l). When all TKIs were compared with each other, 
only IgA levels differed statistically significantly between 
the four groups, imatinib-treated patients having the lowest 
values (p < 0.0001) (Fig. 1p–r).
IgG and IgM levels were the lowest at 12 months 
timepoint
At diagnosis the proportion of patients with IgA, IgG, and 
IgM levels below the lower limit of normal (LLN) was 
0, 11, and 6% of all CML patients, whereas at 12 months 
timepoint Ig levels were more often below the LLN (6, 31 
and 28%, respectively, Table 1). The difference was statis-
tically significant in the case of IgG (p = 0.042) and IgM 
(p = 0.0078). The proportion of patients with low IgA lev-
els did not differ between diagnosis and 12-month analysis 
(p = 0.13).
Next, we performed a paired analysis of Ig levels 
between the diagnosis and 12-month timepoint (Fig.  2). 
At the 12-month analysis, imatinib- and dasatinib-treated 
patients showed significantly lower IgM values. Similar 
trend was also observed with bosutinib patients, but due 
to low number of paired samples (n = 5), no statistical sig-
nificance was reached. In IgG levels, marked decrease was 
observed both in patients treated with imatinib and bosuti-
nib (Fig. 2). Follow-up samples from later timepoints (>12 
months) were not available from all patients, and possible 
correction of Ig levels could not be analyzed.
Lower Ig levels at diagnosis predict 
hypogammaglobulinemia during therapy
All CML patients were divided into two groups based on 
the occurrence of hypogammaglobulinemia (≥2 times 
observed Ig values below the LLN during follow-up) dur-
ing the TKI therapy (Table 1, Supplementary Figs.  1 and 
2). The proportion of the patients with Ig levels below the 
LLN is shown in Table 1 (34% of all CML patients), and 
the percentages did not differ significantly between differ-
ent TKIs (Table  1). The follow-up curves of the separate 
CML patients are shown in Supplementary Fig.  1. Those 
patients, who developed hypogammaglobulinemia, had sig-
nificantly lower IgG and IgM levels already at diagnosis, 
and median Ig levels were significantly lower during fol-
low-up (Fig. 3a–c, Supplementary Fig. 2).
Laboratory parameters and other clinical data were com-
pared between the two groups. Patients with hypogamma-
globulinemia had lower white blood cell counts at the diag-
nosis (p = 0.021, Fig. 3d), and no differences were observed 
in other blood counts, age, or Sokal risk score (data not 
shown).
TKI treatment affects the B cell population in PB 
and BM during the follow-up and these changes are 
related to Ig levels
Paired PB and BM samples for flow cytometric analysis 
were available from imatinib (n = 9), dasatinib (n = 6) and 
nilotinib (n = 8) - treated patients.
The proportion of PB B cells or the absolute PB B cell 
count did not significantly differ between healthy controls 
and CML patients at diagnosis (Fig. 4a, b). When all TKI-
treated patients were analyzed as one group, both relative 
and absolute B cell number dropped significantly dur-
ing TKI therapy (p = 0.0020 and p < 0.0001, respectively) 
(Fig. 3a, b). All TKIs were associated with similar decrease 
in the B cell counts, when the patients were analyzed in 
separate groups (Fig.  4c). The dynamics of developing B 
cells in BM was analyzed in more detail using increasing 
CD45 expression as a marker of maturity in the CD19+ 
B cell population. Imatinib-treated patients, who also 
showed significant decrease of IgA and IgG levels dur-
ing therapy (Figs. 1, 2), had the lowest number of mature 
CD19+CD45high B cells in BM during follow-up when 
compared to the dasatinib group (Fig.  4d–g). The B cell 
Fig. 1  Immunoglobulin values of CML patients during follow-up. 
Dotted lines represent the lower and upper limit of normal Ig val-
ues. a–c Diagnostic phase IgA (a), IgG (b), and IgM (c) values in 
CML patients were compared with healthy controls. Lines  present 
median values. Mann–Whitney t test was used for statistical analysis. 
d–o IgA, IgG, and IgM levels in patients treated with imatinib (d–f), 
dasatinib (g–i), nilotinib (j–l), and bosutinib (m–o) therapy. Lines 
present median values. One-way ANOVA test was used for statisti-
cal analysis. p–r Mean Ig levels of TKI-treated patients at different 
timepoints. I-bars represent SD. Two-way ANOVA test was used for 
statistical analysis
◂
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profile during nilotinib therapy was similar to that of the 
imatinib patients (Fig. 4d–f).
PB B cell subpopulations of CML patients did not differ 
from healthy controls
We performed a more detailed analysis of the PB B cells 
at the 12-month timepoint (range 9–18 months). Samples 
were available from imatinib (n = 11), dasatinib (n = 6), 
nilotinib (n = 6), or bosutinib-treated (n = 5) patients as well 
as healthy controls (n = 8). No significant differences were 
seen in naïve, memory, and transitional B cells or plasma-
blasts when CML patients were compared with healthy 
controls (Fig.  5). Similarly, the occurrence of hypogam-
maglobulinemia during the follow-up did not affect the PB 
B cell populations when different TKIs were compared, 
or when CML patients as one group were compared with 
















































































































































































Fig. 2  Paired Ig samples at the diagnosis and after 12 months of TKI 
therapy. Paired Ig values for diagnostic and 12 month timepoint are 
shown for imatinib (a–c), dasatinib (d–f), nilotinib (g–i), and bosuti-
nib (j–l) –treated CML patients. Dotted lines represent the lower and 
upper limit of normal Ig values. Paired t test was used for statistical 
analysis
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treatment, the proportion of memory B cells tended to be 
larger than in other TKI-treated patients or healthy controls 
and accordingly the proportion of naïve B cells was dimin-
ished (Fig. 5a, b).
Case report: severe hypogammaglobulinemia 
during imatinib treatment
Patient 1 in Table  2 was diagnosed with chronic phase 
CML at the age of 55 years. The Sokal score was 0.66 
(low risk). She used hydroxyurea for 3 weeks, and then 
started imatinib 400  mg qd. After 3 months of treat-
ment she was in complete cytogenetic remission, and 
at 12-month timepoint the BCR-ABL qPCR level was 
0.38% IS. The patient suffered from recurrent respiratory 
tract infections after 9 months of imatinib treatment and 
was treated with several antibiotics for persistent sinusi-
tis/bronchitis. Ig levels were retrospectively assessed in 
stored plasma samples. At diagnosis IgA, IgG, and IgM 
levels were within normal range: 2.76, 6.9, and 1.11 g/l, 
respectively. The reduction of all Ig levels started at the 
3-month timepoint, and at 12 months the patient had 
developed severe hypogammaglobulinemia (Fig.  6a). 
The patient switched to dasatinib at 17-month time-
point and started to receive intravenous gammaglobulin 
(IVIG). However, during dasatinib therapy the patient 
developed proctitis and anemia, and had to switch 
back to imatinib 400  mg OD at 20-month timepoint. 
Currently, the patient has achieved stable MMR with 
imatinib. The patient received IVIG every 4–6 weeks for 
four years, after which the IgG levels were sufficient and 
IVIG was discontinued. Unusually frequent infections 
have not been reported since the start of IVIG therapy.
PB counts showed lymphopenia at 1-, 3-, and 6-month 
timepoints (1.0 × 109/l, 0.9 × 109/l and 1.1 × 109/l, respec-
tively) (Fig. 6b). Simultaneously with the decrease of IgM 
and IgA levels at 3 months, we observed decreased per-
centages of BM mature B cells (Fig. 6c) and PB naïve B 
cells (Fig. 6d).
Correlation of immunoglobulin levels with clinical 
parameters and treatment response
Ig plasma levels were correlated with clinical parameters 
and treatment response in the whole CML patient cohort. 
Higher Sokal score, which is related to the increased 
CML disease burden, was associated with lower levels 
of IgM during the follow-up (p < 0.0001, respectively) 
















































Fig. 3  Lower Ig levels at the diagnosis predicted hypogammaglobu-
linemia during therapy. CML patients were divided into two groups: 
the patients who had normal plasma Ig levels during TKI therapy 
(no hypogamma), and the patients who had ≥2 measured plasma Ig 
values below the lower limit of normal (hypogamma). a–c Median 
diagnostic Ig values were compared between the two groups. d PB 
leukocyte counts at the diagnosis. Lines represent median values and 
dotted lines represent the lower and upper limit of normal Ig values. 
Mann–Whitney t test was used for statistical analysis
1550 J Cancer Res Clin Oncol (2017) 143:1543–1554
1 3
(Supplementary Fig. 3). Sex or age did not affect Ig levels 
(data not shown).
Next, we correlated the Ig levels also with treatment 
response. The achievement of major molecular response 
[MMR, BCR-ABL ≤ 0.1% on the International scale (IS)] 
at 12 months of TKI therapy is a European Leukemia Net 
criterion for optimal response.(Baccarani et  al. 2013) Out 
of 41 CML patients from whom the data were available, 28 
(68%) had achieved a MMR at 12 months. IgM levels were 
significantly lower in the patients who had achieved MMR 
(p < 0.0001), but 13/28 (46%) of those patients were treated 
with dasatinib, and accordingly, the observed decrease of 
IgM values could be due to the overrepresentation of the 
dasatinib patients (Supplementary Fig.  4, Fig.  1i). The 
percentages of different B cell populations in PB and BM 
were not related to the treatment response (data not shown).
Severe infections were not reported in the CML patient 
cohort
All studied CML patients took part in different clinical tri-
als and therefore accurate medical documentation including 
reported infections was available. No major infectious com-
plications were observed among the patients included. One 
of the nilotinib-treated patients had a primary immunodefi-
ciency syndrome manifesting as a selective IgA-deficiency: 
the patient was excluded from the analysis regarding IgA 
values. Of the 24 patients who had low Ig levels during the 

























































































































































Fig. 4  The analysis of B cell populations in PB and BM during TKI 
therapy. a–b The median proportion of B cells of CD45+ lympho-
cytes and absolute number of B cells in healthy controls and all CML 
patients at different timepoints. One-way ANOVA was used for statis-
tical analysis of CML patients’ follow-up data. Mann–Whitney t test 
was used for the comparison of healthy controls and CML patients at 
diagnosis, and for the comparison of CML patients’ diagnostic phase 
and 1 month data. c The comparison of the mean percentage of PB 
B cells of CD45+ lymphocytes during different TKI therapies. I-bars 
represent SD. d–f The mean proportions of mature (d), maturing (e), 
and immature (f) B cells in BM during TKI therapy. I-bars represent 
SD. g Median percentages of mature BM B cells of CD19+ B cells 
at 3 months timepoint. Statistical analysis was done with one-way 
ANOVA and Bonferroni post-test. Two-way ANOVA was used for 
the statistical analysis of the data in panels c–f. BOS bosutinib; DAS 
dasatinib; IM imatinib; NIL nilotinib. *p < 0.05, ***p < 0.001
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Fig. 5  Flow cytometry analysis of PB B cell subclasses. Following 
PB B cell subpopulations were analyzed by flow cytometry: Naïve 
(a), memory (b), marginal zone-like memory (c), class-switched 
memory (d), and plasmablasts (e). Lines represent median values. 
One-way ANOVA was used for statistical analysis between the groups
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TKI therapy, minor infections were reported in 8 (33%) 
cases during the follow-up, whereas, only 1 (3%) of the 34 
patients with normal Ig levels suffered from minor respira-
tory tract infections reported in the medical documentation 
(p = 0.0016).
Discussion
In addition to their main target BCR-ABL1, all available 
TKIs also inhibit several other kinases, which are impor-
tant for the function of the immune system (Hantschel et al. 
2008). Although immunomodulatory effects of different 
TKIs, mainly of imatinib and dasatinib, have previously 
been described, most of these studies have focused on 
describing the effects on the innate and adaptive immune 
systems, thus leaving the humoral immunity less studied. 
To our knowledge, this is the first study to compare the 
in  vivo effects of four different first-line TKIs (imatinib, 
dasatinib, nilotinib, bosutinib) on Ig levels and B cell popu-
lations in chronic phase CML patients.
The plasma Ig values at diagnosis in our CML patient 
cohort did not differ from healthy controls, which is in 
concordance with previous studies (Santachiara et  al. 
2008). However, lower diagnostic Ig levels predisposed 
to the development of hypogammaglobulinemia during 
TKI therapy. In total, 34% of the CML patients developed 
hypogammaglobulinemia during first-line TKI therapy, and 
especially IgG and IgM levels decreased when diagnostic 
values and 12-months analysis were compared. Similar 
observations have been made before in CML patients resist-
ant to or intolerant of interferon-α and subsequently treated 
with second-line imatinib (Steegmann et al. 2003). Another 
study showed, that 42% of CML and 46% of gastrointes-
tinal stromal tumor (GIST) patients who used imatinib as 
a first-line therapy developed hypogammaglobulinemia 
(Santachiara et al. 2008). The role of TKIs on the humoral 
immunity has also been studied in the context of vaccines: 
in a series of CML patients treated with imatinib, dasatinib, 
or nilotinib and vaccinated against influenza virus, TKI 
Table 2  Infections in patients with hypogammaglobulinemia
a The patient with severe hypogammaglobulinemia
Case Reported infections Drug
1a Sinusitis/bronchitis Imatinib
2 Conjunctivitis, common cold Imatinib
3 Conjunctivitis Dasatinib
4 Cystitis caused by E. coli Dasatinib
5 2 episodes of common cold, oral herpes simplex Nilotinib
6 2 episodes of common cold, oral herpes simplex Nilotinib
7 Gastroenteritis, a boil in the skin Nilotinib
8 Common cold Bosutinib
Ig final
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Fig. 6  CML patient with severe hypogammaglobulinemia during 
imatinib therapy. a IgA, Ig, and IgM values during the follow-up. b 
PB leukocyte counts. c Flow cytometry analysis of BM B cell sub-
classes. Mature, maturing, and immature B cells were gated from the 
whole BM B cell population. d Flow cytometry analysis of PB B cell 
subclasses
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therapy was associated with decreased anti-influenza IgM 
titers compared to the healthy controls  (Lavallade et  al. 
2013).
In addition to hypogammaglobulinemia, we also 
observed changes in CML patients’ BM and PB B cell 
populations during the TKI therapy. Imatinib therapy 
diminished especially the proportion of CD45+ mature B 
cells in the bone marrow, while dasatinib was associated 
with the decreased amount of immature B cells. The low 
amount of mature B cells during imatinib therapy is in 
well accordance with noted diminished plasma IgG levels 
as only mature B cells are able to secrete Igs. In another 
study, imatinib therapy has been shown to alter the phe-
notype of BM plasma cells in 60% of the patients (Carulli 
et al. 2010). In this study, abnormal phenotype was also 
associated with the reduced serum gammaglobulin lev-
els (Carulli et al. 2010). Imatinib treatment has also been 
associated with significantly reduced PB memory B cells 
(Lavallade et al. 2013).
During dasatinib treatment, we observed a significant 
decrease in plasma IgM levels during the follow-up. The 
wide inhibition profile of dasatinib includes kinases that 
are important for B cells, for example BTK and LYN 
(Hantschel et  al. 2008), and therefore the potential of 
dasatinib has been previously studied in B cell-related 
disorders like chronic lymphocytic leukemia and man-
tle cell lymphoma with some promising results (McCaig 
et al. 2011; Kim et al. 2015). One earlier study showed, 
that dasatinib reduces the number of human CD19+ 
peripheral B cells (Oksvold et  al. 2015) and inhibits 
pre-B cells and immature IgM+ B cells in murine model 
(Duyvestyn et  al. 2014). When other second-generation 
TKIs with wider inhibitory profile than imatinib are con-
sidered (Hantschel et  al. 2008), bosutinib inhibits simi-
lar kinases as dasatinib, but the effects on B cells have 
not been studied before. There are no previous reports 
on the effects of nilotinib on B cells either, even though 
the drug has a similar kinase targeting profile as imatinib 
(Hantschel et  al. 2008). In our patient cohort, the num-
ber of the bosutinib- and nilotinib-treated patients was 
smaller compared to the imatinib and dasatinib groups 
and the only significant finding in the bosutinib-treated 
patients was a decrease in IgM levels.
Hypogammaglobulinemia predisposes towards infec-
tions that are normally taken care of by antibody responses. 
Although no severe infections were reported in our study 
cohort, minor infections were increased among the patients 
with hypogammaglobulinemia. Previous large clinical tri-
als on the different TKIs have shown some evidence of a 
slightly increased rate of infections in TKI-treated patients 
(Reinwald et  al. 2016). It should be noted that among 52 
patients in our cohort, one imatinib-treated patient devel-
oped severe hypogammaglobulinemia and suffered from 
recurrent respiratory infections. This patient also needed 
constant immunoglobulin therapy for four years, until Ig 
levels were sufficient without replacement.
In conclusion, our results indicate that IgM levels 
decrease in the majority of CML patients during first-line 
TKI therapy, and one-third of these patients eventually 
develop hypogammaglobulinemia. Based on our findings, 
lower Ig values at diagnosis could predict the develop-
ment of hypogammaglobulinemia. Minor infections were 
reported more often in the hypogammaglobulinemia group, 
which should be taken into account during treatment. 
Larger patient cohorts are warranted in order to confirm 
these findings.
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